Original Research Article

Frequency of osteopenia and osteoporosis in patients with multiple sclerosis

Marjan Asadollahi¹, Zahra Hamed²*, Kourosh Gharagozlí¹, Abolfazl Atalu², Behzad Nemati²

¹Department of Neurology, School of Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
²Department of Neurology, School of Medicine, Alavi Hospital, Ardabil University of Medical Sciences, Ardabil, Iran

Received: 06 November 2020
Revised: 30 December 2020
Accepted: 02 January 2021

*Correspondence:
Dr. Zahra Hamed,
E-mail: z.hamed@arums.ac.ir

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: Multiple sclerosis (MS) is one of the most important diseases of the central nervous system and one of the main causes of disability in young and middle age groups. Recent studies show that the risk of osteoporosis and osteopenia in MS patients is higher than the normal population which could be related to many factors. The aim of this study was to determine the frequency of osteopenia and osteoporosis among MS patients.

Methods: This descriptive cross-sectional study was performed on 30 patients with MS. Bone density of patients was assessed by bone mineral density (BMD) method. Necessary demographic and clinical information were collected by a checklist and then analyzed by statistical methods in SPSS version 16.

Results: Of all patients, 36.7% had osteoporosis and osteopenia. According to the results, 86.6% of patients had a decrease in bone density in the pelvic region and 50% in the lumbar spine. 43.3% of patients had osteopenia in the pelvic region and 36.7% in the lumbar spine.

Conclusions: The results showed that BMD was high in MS patients. Due to the problems of walking and lack of balance in these patients and the high probability of falling and fractures among them, paying attention to the problem of osteoporosis by early and repeated performing of BMD.

Keywords: BMD, Interferon, Multiple Sclerosis, Osteopenia, Osteoporosis

INTRODUCTION

MS is a chronic inflammatory disease that affects the brain and spinal cord and causes symptoms such as weakness, imbalance, sensory problems, vision and cognitive problems and gradually limits the patient's performance.¹ The disease has a recurrent or progressive nature and it often involves young people and activists in society and its prevalence is higher in women than men.² Patients with MS have several complications during their illness which one of them is osteoporosis. Secondary osteoporosis and mild fractures are more common in MS patients than in the general people.²³⁴ Recent studies have shown that some cell types, especially T cells, play a key role in osteoporosis.⁵ In inflammatory and autoimmune diseases, T cells are activated and cause bone damage, especially in certain conditions such as estrogen deficiency. Bone regeneration occurs continuously throughout life and bone strength is maintained by removing the damaged bone and replacing it with new bone and this keeps the bone structure stable. This process depends on the production and normal function of osteoclast, osteoblast and osteocyte.⁶ MS disease by impact on normal metabolism and bone regeneration cause to reducing bone density and quality and its susceptibility to fracture.⁷ Imbalance and weakness
caused by the disease, cause to frequent falls of patients and fatigue and muscle weakness also reduce the activity and stimulus of patients. Decreased stimulus and physical activity put mechanical stress on the bone, which causes an imbalance in bone regeneration and destruction of the osteocyte networks. In addition to acquired factors, non-acquired factors such as gender also play a role in the development of osteoporosis in MS patients. Studies have shown that bone density is lower in sick women than in sick men. Drugs such as glucocorticoids and other immunomodulatory drugs used to treat MS also play a role in causing osteoporosis. Epidemiological studies have shown that the risk of bone fracture after oral treatment with glucocorticoids depending on the dose of the drug, increases the duration of its use. The role of vitamin D in bone homeostasis is well known and the use of vitamin D to prevent and treat osteoporosis is obvious and MS patients have a higher prevalence of vitamin D deficiency than other people. Depression is another complication of multiple sclerosis which cause to non-receiving proper treatment and reduces stimulus. The use of antidepressants is common in MS patients due to secondary depression. Serotonin antidepressants are associated with a high risk of fractures in osteoporosis. The degree and duration of disability of MS patients which measured by EDSS is the most important factors determining the rate of osteoporosis in MS patients, which is related to their BMD. BMD is a method of measuring bone density using X-rays. It measures bone density and determines bone fragility before a fracture occurs. In EDSS below 6, the patient has good dynamic function, in EDSS about 5-6, patients can walk a few meters with mutual assistance and in EDSS equal seven, a patient needs a wheelchair. In EDSS above seven, patients should be screened intermittently for BMD.

Decreased physical functioning, pain, excessive fatigue, suboptimal nutrition (particularly low vitamin D), and adverse effects of medications are among the many factors contributing to bone loss in MS.

Despite the fact that MS patients are at high risk of bone fractures and in case of fractures, their problems are added and they enter a vicious cycle that leads to both increased osteoporosis and disability, unfortunately the evaluation of bone health in MS patients is often forgotten and is not part of the treatment protocol of patients, therefore, by conducting this study we decided to estimate the frequency of osteoporosis and osteopenia among patients with MS.

**METHODS**

This descriptive cross-sectional study was performed on 30 MS patients selected randomly by random sampling method from all patients with MS who referred to the neurology clinic of Loghman Hakim Hospital in Tehran from April 2016 to April 2018.

**Inclusion criteria**

Inclusion criteria included patients' consent to participate in the study and MS-confirmed disease based on history, examination and MRI results which confirmed by a physician.

**Exclusion criteria**

Patients with inflammatory and systemic diseases such as autoimmune and endocrine diseases were excluded from the study.

**Data collection method**

Data collection method through a checklist containing demographic information such as age and sex and clinical information such as duration of disease, disease progression or RR, corticosteroids and interferon intake, BMI (kg/m²), serum level test results Vitamin D ng/mm and EDSS. Bone mineral density was measured based on the BMD evaluation system at the same center and dynamic function was based on the EDSS scoring system, which was graded from one to 10 depending on the severity of the conflict. T score between -1 and -5 was considered as osteopenia and less than -2.5 was considered as osteoporosis.

**Statistical analysis**

The collected data were analyzed using SPSS16 and Chi-Square, Mann-Whitney and Kruskal-Wallis statistical tests and p<0.05 was considered as significant.

**Ethical approval**

The result of this study extracted from MD. Fellow thesis in neurology and approved by Shahid Beheshti University of Medical Sciences, Tehran, Iran.

**RESULTS**

Of 30 patients, 60% were female and the rest were male. 36.7% of all patients had osteoporosis and osteopenia.

The average age of patients was 36.2±9.5 years (range: 21-55). 10% of patients had BMI above 30 that all of whom had osteopenia. The average age of patients with normal BMI was 35.2±9 and high BMI was 10.6±39 years and the difference was not statistically significant. 66.7% of patients were taking interferon and the difference between three healthy, osteoporotic and osteopeniac groups was significant. Glucocorticoids use also showed that 43.4% of patients had 3-5 pulses per day. By measurement of serum vitamin D levels results showed that the majority of patients, especially patients with osteoporosis, had low levels of vitamin D. EDSS was 23.3% of patients from 6-7 that most of whom were generally seen in the osteopenia group (Table 1).
Table 1: Compare the characteristics of patients with osteoporosis and osteopenia.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Condition</th>
<th>Total %</th>
<th>Osteoporosis %</th>
<th>Osteopenia %</th>
<th>Normal %</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td>Man</td>
<td>40</td>
<td>12</td>
<td>16.7</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Woman</td>
<td>60</td>
<td>18</td>
<td>10</td>
<td>3</td>
<td>8</td>
</tr>
<tr>
<td>BMI</td>
<td>&lt;30</td>
<td>90</td>
<td>27</td>
<td>13.3</td>
<td>10</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>&gt;30</td>
<td>10</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>EDSS</td>
<td>≤6</td>
<td>70</td>
<td>21</td>
<td>26.7</td>
<td>8</td>
<td>13.3</td>
</tr>
<tr>
<td></td>
<td>06-7</td>
<td>23.3</td>
<td>7</td>
<td>16.6</td>
<td>5</td>
<td>6.7</td>
</tr>
<tr>
<td></td>
<td>&gt;7</td>
<td>6.7</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0.7</td>
</tr>
<tr>
<td>Duration</td>
<td>New case</td>
<td>16.7</td>
<td>5</td>
<td>6.7</td>
<td>2</td>
<td>3.3</td>
</tr>
<tr>
<td></td>
<td>&lt;5 years</td>
<td>20</td>
<td>6</td>
<td>10</td>
<td>3</td>
<td>3.3</td>
</tr>
<tr>
<td></td>
<td>&gt;5 years</td>
<td>60</td>
<td>18</td>
<td>26.7</td>
<td>8</td>
<td>30</td>
</tr>
<tr>
<td>Course</td>
<td>Relapsing-remitting</td>
<td>53.3</td>
<td>16</td>
<td>20</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>Progressive</td>
<td>40</td>
<td>12</td>
<td>20</td>
<td>6</td>
<td>20</td>
</tr>
<tr>
<td>Interferon</td>
<td>Users</td>
<td>66.7</td>
<td>20</td>
<td>20</td>
<td>6</td>
<td>36.7</td>
</tr>
<tr>
<td>Use</td>
<td>Non users</td>
<td>30</td>
<td>9</td>
<td>23.3</td>
<td>7</td>
<td>3.3</td>
</tr>
<tr>
<td>Glucocorticoid Use</td>
<td>&lt;3 pulse</td>
<td>40</td>
<td>12</td>
<td>20</td>
<td>6</td>
<td>13.3</td>
</tr>
<tr>
<td></td>
<td>3-5 pulse</td>
<td>43.4</td>
<td>13</td>
<td>16.5</td>
<td>5</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>&gt;5 pulse</td>
<td>10</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>3.3</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>Normal</td>
<td>20</td>
<td>6</td>
<td>10</td>
<td>3</td>
<td>6.7</td>
</tr>
<tr>
<td>Level</td>
<td>Low</td>
<td>70</td>
<td>21</td>
<td>33.3</td>
<td>10</td>
<td>26.7</td>
</tr>
</tbody>
</table>

![Image](Figure 1: Frequency of osteoporosis and osteopenia by involvement location.)

Of 30 patients, 86.6% had osteopenia or osteoporosis that all of whom had a decrease in bone density in the pelvic region and 15 (50%) in the lumbar spine. 43.3% of patients had osteopenia in the pelvic region and 36.7% in the lumbar spine (Figure 1). The average age of patients with normal bone density was 34.8±13.4 years, in osteopenia patients was 35.7±8.2 and in osteoporosis patients was 37.2±10.2 but the difference between them was not statistically significant.

DISCUSSION

In healthy people, bone mass increases up to age of 25-30 and begins to decline after the age of 40.19 This decline occurs in both age dependent sexes. In the present study, 36.7% of all patients in both sexes had a decrease in bone density, osteopenia and osteoporosis but the decrease in BMD was not related to gender. Maximum bone mass per person depends on various causes that about 70% of which depend on hereditary factors and about 30% to environmental factors such as physical activity, hormone status, amount of vitamins and minerals needed for bone metabolism, chronic diseases and effective drugs on bone building.20 The results of this study showed that 86.6% of people with MS have a decrease in bone density. Agha Ali et al in a study on patients over 60 years of age showed that the prevalence of osteoporosis was 19.9% and osteopenia was 36.2% which was lower than the present study and this statistics confirm that the prevalence of osteoporosis and osteopenia in ms patients is more than normal people over 60 years.21

In a study by Sioka et al, found that multiple sclerosis was associated with decreased bone mass and a high incidence of osteoporosis.22 Another study by Marie et al in 2009 on 9,346 people at the North American Research Center found that 27.2% of MS patients had reduced bone mass and 15% had fractures. They also showed that MS patients often have high risk factors for bone loss and fractures.12 In this study, all patients in the pelvic region and 15 patients (50%) in the lumbar spine had a decrease in bone density. In a 2011 study on 99 patients and 159 controls, Moen et al found that 50.5% of patients and 37.1% of controls had osteoporosis or osteopenia, which was more common in the lumbar spine and pelvis.23 The results of the present study showed that the rate of
osteopenia and osteoporosis in the pelvic bones was significantly higher than the bones of the lumbar spine, which is consistent with the results of other studies in this regard. In this study, no significant relationship was found between serum vitamin D levels and osteoporosis, but 60% of patients with osteopenia and osteoporosis had low vitamin D levels. According to studies, markers of bone metabolism such as vitamin D and calcium levels are not a reliable and suitable method for diagnosing of osteoporosis in patients. But in a study by Nieves, there was a significant association between low levels of vitamin D and low BMD. In this study similar to Zorzon study on 25 MS patients, there was no relationship between patients' BMD and corticosteroids. This study the rate of osteoporosis in both the pelvic and lumbar spine was lower in those who took interferon than in those who were not treated with the drug, which was more especially in the pelvis. Interferon beta increases BMD through its inhibitory effect on osteoclasts. Compman et al showed that, the Z score of patients treated and untreated with interferon was not different. The difference in the results of these studies was probably due to differences in the number of patients, the duration of the disease and other factors influencing BMD. According to the results of this study, there was an inverse relationship between EDSS and BMD and by increasing EDSS the patient's BMD decreased, especially in the lumbar spine. More serious motor problems and more severe gait disorders due to inactivity and immobility are likely to reduce bone density in this group of patients. These results show that the lower the patient's dynamic were correlated with the lower the pelvic and lumbar spine BMD. But in some studies, there was no significant relationship between EDSS and BMD.

CONCLUSION

The results of the present study showed that the frequency of osteopenia and osteoporosis in MS patients was higher than normal people. Due to the problems of walking and lack of balance in these patients and the high probability of falling and fractures among them, paying attention to the problem of osteoporosis by early and repeated performing of BMD will cause timely diagnosis and treatment of patients with osteoporosis and osteopenia.

Therefore it is suggested that all MS patients should be considered in the high risk group and by considering the risk factors such as vitamin D deficiency and upper EDSS, all patients should be evaluated for osteopenia and osteoporosis. Despite the importance of this issue, there is still no guideline on BMD in MS patients and more studies are needed to develop such a guideline.

Finally, it will propose a strategy for timely assessment and early management of osteoporosis due to all forms of MS, processes which can be initiated during inpatient rehabilitation and continued in either long-term care or in a community setting.

Funding: No funding sources
Conflict of interest: None declared

Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES


